The study revealed that GLP-1 receptor agonists were correlated with a 27% reduction in mortality, a 16% decrease in the risk of severe disease, and a 14% decrease in the probability of hospitalization for COVID-19 compared to insulin. Here, GLP1R is linked to COVID-19.